Add BrightSurf on Google Email

Ohio State University Wexner Medical Center


Can better gut health help patients with ovarian cancer tolerate chemotherapy?

A new Ohio State University clinical trial investigates whether probiotics can help patients with ovarian cancer better tolerate chemotherapy. The study aims to reduce treatment side effects and improve quality of life. Researchers will examine changes in the gut microbiome and its link to treatment response.

SourceOhio State University Wexner Medical Center·TypeRandomized controlled/clinical trial·DateOct 20, 2026

‘Smart bomb’ combination attacks triple-negative breast cancer in preclinical study

Researchers at Ohio State University Wexner Medical Center developed a combination treatment that targets CD276 protein and disrupts mitochondria, killing cancer cells and slowing tumor growth in preclinical models of triple-negative breast cancer. The findings suggest a possible new approach to treat this hard-to-treat form of breast ...

SourceOhio State University Wexner Medical Center·JournalCell Reports Medicine·TypeExperimental study·DateOct 20, 2026

Clinical trial shows positive results of enhanced CAR T-cell therapy for patients with B-cell blood cancers

A phase I clinical trial at Ohio State University Wexner Medical Center demonstrated positive results for enhanced CAR T-cell therapy targeting B-cell blood cancers. The treatment resulted in minimal side effects and improved treatment outcomes for patients with relapsed or treatment-resistant B-cell blood cancers.

SourceOhio State University Wexner Medical Center·JournalBlood Cancer Discovery·DateOct 13, 2026

Study finds pregnancy stress may change placenta signals linked to fetal brain development

Researchers at Ohio State University Wexner Medical Center found that chronic stress during pregnancy changes how the placenta communicates with the developing fetus, affecting early brain development. Prenatal stress alters placental signaling and opposes maternal immune activation effects in the fetal brain.

SourceOhio State University Wexner Medical Center·JournalMolecular Psychiatry·DateOct 13, 2026

ASCO 2026: Ohio State researchers highlight cancer drug donation program, lung and breast cancer treatment, Lynch syndrome screening, access to clinical trials and more

Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.

ASCO 2025: Pancreatic cancer blood tests, genetic predictors of breast cancer survival and sarcoma treatment response prediction tools among Ohio State findings

Researchers at Ohio State University have developed blood tests to diagnose pancreatic cancer and predict treatment outcomes. Genetic information can also help predict breast cancer survival rates, while a new blood test may improve treatment response for patients with advanced sarcoma. These findings offer promising tools for early de...

Study reveals why women tend to have faster heartbeats, men more irregular rhythms

Researchers at Ohio State University discovered that women's hearts beat faster due to higher levels of genes like TBX3 and HCN1. In contrast, men's hearts are more prone to irregular rhythms like atrial fibrillation, linked to inflammation and collagen production.

SourceOhio State University Wexner Medical Center·JournalCirculation Arrhythmia and Electrophysiology·TypeComputational simulation/modeling·DateMay 15, 2025

AACR 2025: Colon cancer risk reduction, predicting melanoma spread and new drug therapies among Ohio State findings

Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.

Ohio State study reveals new insights into neurodegeneration using human ‘mini brains’

Researchers at Ohio State University Wexner Medical Center have discovered a new way that neurons act in neurodegeneration by studying human neural organoids from patients with frontotemporal lobar degeneration (FTLD). They found GRAMD1B plays a significant role in managing cholesterol and lipid stores, which are linked to brain diseas...

SourceOhio State University Wexner Medical Center·JournalNature Communications·TypeExperimental study·DateApr 9, 2025

Survey: While most Americans use a device to monitor their heart, few share that data with their doctor

A national survey of 1,008 Americans found that nearly two-thirds use a device to monitor their heart health, but only one in four shares the data with their doctor. This lack of sharing can lead to delayed diagnosis and treatment, emphasizing the importance of proactive communication between patients and healthcare providers.

Outcomes worse for patients who develop pressure sores after acute spinal cord injury

A study published in JAMA Network Open found that hospital-acquired pressure ulcers are associated with poorer neurological outcomes and reduced motor function in patients with acute cervical spinal cord injury. The findings suggest that preventing pressure ulcers can help protect these patients and lead to improved medical care.

SourceOhio State University Wexner Medical Center·JournalJAMA Network Open·TypeObservational study·DateDec 6, 2024

First-ever randomized clinical trial uses telehealth for suicide prevention

A new study published in JAMA Network Open found that brief cognitive behavioral therapy via video telehealth reduces suicide attempts and suicidal ideation, providing critical insight into treatment options for those struggling with suicidal thoughts. The study also shows that this therapy is effective in reducing depressive symptoms.

SourceOhio State University Wexner Medical Center·JournalJAMA Network Open·TypeRandomized controlled/clinical trial·DateNov 12, 2024